New product: Ruxience (rituximab) concentrate for solution for infusion

This biosimilar from Pfizer is licensed for the range of indications of the reference product, MabThera (Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis and pemphigus vulgaris).

electronic Medicines compendium